Profound Medical Corporation (NASDAQ:PROF) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET
Company Participants
Stephen Kilmer - IR
Arun Menawat - CEO
Rashed Dewan - CFO
Mathieu Burtnyk - COO
Conference Call Participants
Rick Wise - Stifel
Ben Haynor - Lake Street Capital Markets
Rahul Sarugaser - Raymond James
Michael Sarcone - Jefferies
Scott McAuley - Paradigm Capital
Brian Gagno - Gagnon Securities
Operator
Welcome to the Profound Medical Second Quarter 2024 Financial Results conference call. [Operator Instructions]. I would now like to hand the conference over to your first speaker today, Stephen Kilmer, Investor Relations. Please go ahead.
Stephen Kilmer
Thank you. Good afternoon, everyone. Let me start by pointing out that this conference call will include forward looking statements within the meeting of applicable securities laws in the United States and Canada. All forward looking statements are based on Profound's current beliefs, assumptions and expectations, and relate to, among other things, any expressed or implied statements or guidance regarding current or future financial performance and position, including the company's 2024 financial outlook and related assumptions, the expectations regarding the efficacy of Profound's technology in the treatment of prostate cancer, BPH, uterine fibroids, palliative pain treatment and osteoma and its future revenues and financial results.
Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. No forward looking statement can be guaranteed. Listeners are cautioned not to place undue reliance on these forward looking statements, which speak only as of the date of this conference call. Profound undertakes no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events, or otherwise other than is required by law. Representing the company today are Dr Arun Menawat, Profound's, Chief Executive Officer, Rashed Dewan, the Company's Chief Financial Officer, and Dr. Mathieu Burtnyk Profound's, Chief Operating Officer.
With that said, I'll now turn the call over to Rashed.
Rashed Dewan
Good afternoon everyone, and welcome to our second quarter 2024 conference call. On behalf of the management team and everyone at Profound, I would like to thank you for your ongoing interest in our company. For those of you who are shareholders, we appreciate your continued interest and support. I will turn the call over to Mathieu in a moment to provide updates on TULSA clinical publications, utilization trends, the CAPTAIN clinical trial and reimbursement. However, before I do I would like to provide a brief summary of our second quarter 2024 financial results.